DENVER, July 1, 2014 /PRNewswire/ Dr James Ehrlich MD
A recent New York Times article (“Threat Grows from Liver Illness Tied to Obesity”, June 13 2014) alerting millions to the growing prevalence and seriousness of fatty liver disease revealed the concerning reality about therapeutic options. There are currently no drugs approved for either NAFLD (nonalcoholic fatty liver disease) or NASH (nonalcoholic steatohepatitis), the two faces of fatty liver disease. Affecting 10% of children and 20% of adults in the United States, fatty liver disease is a risk factor for heart disease, diabetes and cirrhosis and is projected to become the most common reason for liver transplantations.
The strikingly beneficial effect of BergaMet™ on Italian patients with fatty liver disease has prompted a nationwide call for US based research proposals from academic liver specialists to confirm the published results from Europe.
Published research from two European universities has proven that a highly concentrated proprietary extract of the Calabrian bergamot fruit (38% citrus bergamot extract, BergaMet™/NatHealthsolutions) powerfully benefits patients with nonalcoholic fatty liver disease (NAFLD).
In a study conducted by Professor G. Rosano (San Raffaelle Pisana Clinic, Rome) involving investigators from the US, Australia and the University of Catanzaro (led by Professor V. Mollace), 107 patients with metabolic syndrome and NAFLD were treated for 120 days with polyphenol-rich 38% citrus bergamot extract (BergaMet™). Striking effects were noted on both liver function and structure. Ultrasound of abdominal structures (“hepatorenal ratio”) revealed a dramatic 50% reduction in liver fat, while a biochemical analysis (“steato test”) demonstrated a 40% improvement in scores. Bergamot therapy converted the typical patient from severe steatosis (fatty liver) to the moderate category in 12 weeks. Standard liver function blood tests also quickly normalized in the majority of patients.
According to Professor Rosano “Based upon our research, bergamot polyphenol appears to be a clinically useful and effective treatment for patients with fatty liver disease, especially in those with abnormal lipids”. The complete results of this study have been published in a peer reviewed journal and the liver data has been submitted in abstract form to the 2014 annual meeting of the American College of Gastroenterologists.
A separate group of investigators led by Professor F. Andreozzi (Polyclinico Umberto I, Rome) evaluated an “integrator” (Tokaber) consisting of citrus bergamot extract/oleo european/ascorbic acid given to 40 patients with fatty liver disease for a period of 60 days. Highly significant improvements in liver function tests were demonstrated in this study. The studies demonstrated strikingly beneficial results of BPF on patients with fatty liver disease at a level heretofore not shown for any other product or drug.
According to co-investigator Professor Vincenzo Mollace of the University of Catanzaro,”our studies in both rats and humans have consistently demonstrated that therapy with bergamot counters the accumulation of fat in the liver while prompting its elimination. We have proven and published a significant and dramatic improvement in both liver function and structure in these patients while decreasing cardiometabolic risk after a few months of bergamot therapy.”
Dr. Shahid M. Malik of the Center for Liver Diseases at the University of Pittsburgh Medical Center is one of the liver specialists quoted in the NY Times article. He states “fatty liver disease is a rising epidemic that is overwhelming our transplant centers. Current therapies have been largely ineffective. My initial review of the BPF (BergaMet ) studies are highly promising and worth presenting to our team for consideration of research at our institution.”
Dr. James Ehrlich, an advisor to NatHealthSolutions states “the New York Times piece brought needed attention to an underappreciated worldwide epidemic with significant health and economic consequences. We are very gratified that two scientific studies conducted in Europe imply that BergaMet may be the best currently available therapy for these serious and common conditions. We are very confident these initial results will attract leading US based liver specialists to conduct studies to further understand the proper roles of BergaMet for patients suffering from fatty liver disorders”